<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; story</title>
	<atom:link href="http://www.tapanray.in/tag/story/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Shift from Disease Centered Care To Patient-Goals Directed Care In The New Normal</title>
		<link>http://www.tapanray.in/shift-from-disease-centered-care-to-patient-goals-directed-care-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shift-from-disease-centered-care-to-patient-goals-directed-care-in-the-new-normal</link>
		<comments>http://www.tapanray.in/shift-from-disease-centered-care-to-patient-goals-directed-care-in-the-new-normal/#comments</comments>
		<pubDate>Sun, 09 Aug 2020 23:50:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[cases]]></category>
		<category><![CDATA[centered]]></category>
		<category><![CDATA[centricity]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[directed]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[goal]]></category>
		<category><![CDATA[GPs]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[specialists]]></category>
		<category><![CDATA[story]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10218</guid>
		<description><![CDATA[In the initial days of the first quarter of 2020, no one could fathom that just within the next 4 months over two million fellow citizens will get infected by an unknown virus, recording over 45,500 deaths. Many authorities may &#8230; <a href="http://www.tapanray.in/shift-from-disease-centered-care-to-patient-goals-directed-care-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shift-from-disease-centered-care-to-patient-goals-directed-care-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is India A Success Story With Biosimilar Drugs?</title>
		<link>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-india-a-success-story-with-biosimilar-drugs</link>
		<comments>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/#comments</comments>
		<pubDate>Mon, 25 Feb 2019 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[labyrinth]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pathways]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[revenue]]></category>
		<category><![CDATA[story]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[uncertainty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9422</guid>
		<description><![CDATA[How Indian generic companies are expanding, if not shifting their business focus on biosimilar and complex generic drugs, may be a current trend of general discourse &#8211; but the initiative is not a current one. This journey commenced decades ago &#8230; <a href="http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Threats to Indian Generics: Failing in US Inspections is Just Half The Story</title>
		<link>http://www.tapanray.in/threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story</link>
		<comments>http://www.tapanray.in/threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story/#comments</comments>
		<pubDate>Wed, 26 Feb 2014 09:44:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[Cleveland]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[failing]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[half]]></category>
		<category><![CDATA[Hamburg]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[inspection]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[Margaret]]></category>
		<category><![CDATA[Ohio]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[story]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[Toansa]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Wellbutrin XL]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5027</guid>
		<description><![CDATA[At a recent event of the American Enterprise Institute, Dr. Harry Lever, a senior cardiologist at the Cleveland Clinic in Ohio, reportedly expressed his concern based on his personal experience regarding inconsistent quality among Indian generics. As a result, he requires switching patients &#8230; <a href="http://www.tapanray.in/threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Fire in The Blood”: A Ghastly Patents Vs Patients War &#8211; for Pricing Freedom?</title>
		<link>http://www.tapanray.in/fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom</link>
		<comments>http://www.tapanray.in/fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom/#comments</comments>
		<pubDate>Mon, 07 Oct 2013 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[blood]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[CSR]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Dylan]]></category>
		<category><![CDATA[fire]]></category>
		<category><![CDATA[ghastly]]></category>
		<category><![CDATA[Gray]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Mohan]]></category>
		<category><![CDATA[obscene]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[story]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[war]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3776</guid>
		<description><![CDATA[International award winning documentary film, &#8216;FIRE IN THE BLOOD&#8217; could possibly set a raging fire in your blood too, just like mine. It made me SAD, REFLECTIVE and ANGRY, prompting to share &#8216;MY TAKE AWAYS&#8217; with you on this contentious subject, immediately after I put &#8230; <a href="http://www.tapanray.in/fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
